Bayer Backs Vesigen To Improve Cell and Gene Therapy Delivery
New Biotech Approach For Gene Editing, mRNA
Executive Summary
Serial entrepreneur Robert Millman is leading the new biotech which thinks it has the answer to getting CRISPR and RNA-based therapies into cells more efficiently
You may also be interested in...
Deal Watch: Merck Gets Rights To Yumanity’s Preclinical ALS, FTLD Candidates
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.
Bayer Eyes Indications Beyond BlueRock's Initial Focus With $240m-Plus Buyout
Bayer will acquire the 40.8% of BlueRock that it doesn't already own as the firm's largest investor via a $225m series A round in 2016. A clinical trial for BlueRock's Parkinson's disease candidate is expected to begin later this year.
Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
Need a specific report? 1000+ reports available
Buy Reports